Repligen (RGEN) Tops Q2 EPS by 15c, Revenues Beat; Raises FY20 EPS/Revenue Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Tesla acquires AI hardware company for up to $2 billion in stock
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
- Bel Fuse acquires dataMate ethernet business for $16 million
Repligen Reports Second Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance
July 30, 2020 7:30 AM EDTReports record quarterly revenue of $87.5 millionOverall revenue grew 24% year-over-year, with organic growth of 19% Raises revenue guidance to $332-$340 million for full year 2020, representing 18%-21% organic growthCompletes acquisition of silicone molding and tubing manufacturer Engineered Molding Technology
WALTHAM, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter of 2020. Provided in this press release are financial highlights for the three- and six- month periods... More
